Boothbay Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

Boothbay Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.98M	Sell	147,402 -854,326	-85%	-$23.4M	0.05%	424
2026 Q1	$27.1M	Buy	1,001,728 +9,646	+1%	+$283K	0.35%	23
2025 Q4	$36M	Buy	992,082 +49,456	+5%	+$1.98M	0.54%	17
2025 Q3	$35.7M	Buy	942,626 +125,700	+15%	+$2.72M	0.52%	19
2025 Q2	$11.1M	Sell	816,926 -106,477	-12%	-$1.54M	0.21%	106
2025 Q1	$14.7M	Buy	923,403 +273,380	+42%	+$3.14M	0.39%	33
2024 Q4	$8M	Buy	650,023 +44,067	+7%	+$576K	0.2%	144
2024 Q3	$7.34M	Buy	605,956 +181,773	+43%	+$2.2M	0.17%	154
2024 Q2	$4.96M	Buy	+424,183	New	+$5.34M	0.12%	230

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boothbay Fund Management's MLYS Position: Q2 2026 in Review

Boothbay Fund Management reduced its Mineralys Therapeutics (MLYS) stake by 85% in Q2 2026, selling an estimated $23.4M and leaving 147,402 shares worth $3.98M. The position accounts for 0.05% of the portfolio, ranked #424.

Boothbay Fund Management first reported a position in MLYS in Q2 2024 and has held it in 9 quarters since. The position peaked at $36M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Boothbay Fund Management held 147,402 shares of Mineralys Therapeutics worth $3.98M as of Q2 2026.
Boothbay Fund Management sold 854,326 Mineralys Therapeutics shares in Q2 2026, an estimated $23.4M.
Mineralys Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #424 holding.
Boothbay Fund Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 9 quarters since.
Boothbay Fund Management's Mineralys Therapeutics position peaked at $36M in Q4 2025.
226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.